Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients

Clinical Cancer Research

Volumn 14, Issue 3, 2008, Pages 764-771

  Gagnon, Audrey ^a   Kim, Jae Hoon ^b   Schorge, John O ^c   Ye, Bin ^a   Liu, Brian ^a   Hasselblatt, Kathleen ^a   Welch, William R ^a   Bandera, Christina A ^d   Mok, Samuel C ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CA 125 ANTIGEN; MESSENGER RNA; PROTEIN ANTIBODY; PSORIASIN; TUMOR ANTIGEN;

ADULT; AMINO ACID SEQUENCE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TWO DIMENSIONAL DIFFERENTIAL GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; VALIDATION PROCESS;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOGLOBULIN G; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM;

EID: 38949161926     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0856     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Rosen DG, Wang L, Atkinson JN, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005;99:267-77.
3. Bast RC, Jr., Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers 1998;13:179-87.
4. Bast R C, Jr., Badgwell D, Lu Z, et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005;15 Suppl 3:274-81.
5. Kong F, Nicole White C, Xiao X, et al. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol 2006;100:247-53.
6. Sahin U, Tureci O, Schmitt H, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A 1995;92:11810-3.
7. Lu H, Goodell V, Disis ML. Targeting serum antibody for cancer diagnosis: a focus on colorectal cancer. Expert Opin Ther Targets 2007;11:235-44.
8. Scanlan MJ, Chen YT, Williamson B, et al. Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer 1998;76:652-8.
9. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E. Translation initiation factor eIF-4γ is encoded by an amplified gene and induces an immune response in squamous cell lung carcinoma. Hum Mol Genet 1997;6:33-9.
10. Chinni SR, Gercel-Taylor C, Conner GE, Taylor DD. Cathepsin D antigenic epitopes identified by the humoral responses of ovarian cancer patients. Cancer Immunol Immunother 1998;46:48-54.
11. Kim JH, Herlyn D, Wong KK, et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 2003;9:4782-91.
12. Kotecha SA, Schlichter LC. A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation. J Neurosci 1999;19:10680-93.
13. Kounnas MZ, Loukinova EB, Stefansson S, et al. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin. J Biol Chem 1995;270:13070-5.
14. Luo LY, Herrera I, Soosaipillai A, Diamandis EP. Identification of heat shock protein 90 and other proteins as tumour antigens by serological screening of an ovarian carcinoma expression library. Br J Cancer 2002;87:339-43.
15. Li Y, Karjalainen A, Koskinen H, et al. p53 autoantibodies predict subsequent development of cancer. Int J Cancer 2005;114:157-60.
16. Stockert E, Jager E, Chen YT, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
17. Qin S, Ferdinand AS, Richie JP, O'Leary MP, Mok SC, Liu BC. Chromatofocusing fractionation and two-dimensional difference gel electrophoresis for low abundance serum proteins. Proteomics 2005;5:3183-92.
18. Tsao SW, Mok SC, Fey EG, et al. Characterization of human ovarian surface epithelial cells immortalized by human papilloma viral oncogenes (HPV-E6E7 ORFs). Exp Cell Res 1995;218:499-507.
19. Kim JH, Skates SJ, Uede T, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002;287:1671-9.
20. Gray CW, Ward RV, Karran E, eta l. Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response. Eur J Biochem 2000;267:5699-710.
21. Broome AM, Ryan D, Eckert RL. S100 protein subcellular localization during epidermal differentiation and psoriasis. J Histochem Cytochem 2003;51:675-85.
22. Ruse M, Broome AM, Eckert RL. S100A7 (psoriasin) interacts with epidermal fatty acid binding protein and localizes in focal adhesion-like structures in cultured keratinocytes. J Invest Dermatol 2003;121:132-41.
23. Brouard MC, Saurat JH, Ghanem G, Siegenthaler G. Urinary excretion of epidermal-type fatty acid-binding protein and S100A7 protein in patients with cutaneous melanoma. Melanoma Res 2002;12:627-31.
24. El-Rifai W, Moskaluk CA, Abdrabbo MK, et al. Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 2002;62:6823-6.
25. Emberley ED, Murphy LC, Watson PH. S100A7 and the progression of breast cancer. Breast Cancer Res 2004;6:153-9.
26. Ostergaard M, Wolf H, Orntoft TF, Celis JE. Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 1999;20:349-54.
27. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005;353:1224-35.
28. Erkanli A, Taylor DD, Dean D, et al. Application of Bayesian modeling of autologous antibody responses against ovarian tumor-associated antigens to cancer detection. Cancer Res 2006;66:1792-8.
29. Chatterjee M, Mohapatra S, Ionan A, et al. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res 2006;66:1181-90.
30. Zheng Y, Xu Y, Ye B, et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 2003;98:2576-82.
31. Nesterova M, Johnson N, Cheadle C, Cho-Chung YS. Autoantibody biomarker opens a new gateway for cancer diagnosis. Biochim Biophys Acta 2006;1762:398-403.
32. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
33. Soussi T. p53 antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000;60:1777-88.
34. Zalcman G, Schlichtholz B, Tredaniel J, et al. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. Clin Cancer Res 1998;4:1359-66.
35. Madsen P, Rasmussen HH, Leffers H, et al. Molecular cloning, occurrence, and expression of a novel partially secreted protein "psoriasin" that is highly up-regulated inpsoriatic skin. J Invest Dermatol 1991;97:701-12.
36. Moog-Lutz C, Bouillet P, Regnier CH, et al. Comparative expression of the psoriasin (S100A7) and S100C genes in breast carcinoma and co-localization to human chromosome 1q21-q22. Int J Cancer 1995;63:297-303.
37. Leygue E, Snell L, Hiller T, et al. Differential expression of psoriasin messenger RNA between in situ and invasive human breastcar cinoma. Cancer Res 1996;56:4606-9.
38. Al-Haddad S, Zhang Z, Leygue E, et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999;155:2057-66.
39. Jinquan T, Vorum H, Larsen CG, eta l. Psoriasin: a novel chemotactic protein. J Invest Dermatol 1996;107:5-10.
40. Opdenakker G, Dillen C, Fiten P, et al. Remnant epitopes, autoimmunity and glycosylation. Biochim Biophys Acta 2006;1760:610-5.